TrialCell reports. Medicine2026

Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.

Casey R Ager et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.